BIOMAT Database Logo BIOMAT Database Logo

Elimination of MYCN-Amplified Neuroblastoma Cells by Telomerase-Targeted Oncolytic Virus via MYCN Suppression. 2020

Terutaka Tanimoto, and Hiroshi Tazawa, and Takeshi Ieda, and Hiroshi Nouso, and Morimichi Tani, and Takanori Oyama, and Yasuo Urata, and Shunsuke Kagawa, and Takuo Noda, and Toshiyoshi Fujiwara
Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.

Neuroblastoma (NB) is a primary malignant tumor of the peripheral sympathetic nervous system. High-risk NB is characterized by MYCN amplification and human telomerase reverse transcriptase (hTERT) rearrangement, contributing to hTERT activation and a poor outcome. For targeting hTERT-activated tumors, we developed two oncolytic adenoviruses, OBP-301 and tumor suppressor p53-armed OBP-702, in which the hTERT promoter drives expression of the viral E1 gene for tumor-specific virus replication. In this study, we demonstrate the therapeutic potential of the hTERT-driven oncolytic adenoviruses OBP-301 and OBP-702 using four human MYCN-amplified NB cell lines (IMR-32, CHP-134, NB-1, LA-N-5) exhibiting high hTERT expression. OBP-301 and OBP-702 exhibited a strong antitumor effect in association with autophagy in NB cells. Virus-mediated activation of E2F1 protein suppressed MYCN expression. OBP-301 and OBP-702 significantly suppressed the growth of subcutaneous CHP-134 tumors. Thus, these hTERT-driven oncolytic adenoviruses are promising antitumor agents for eliminating MYCN-amplified NB cells via E2F1-mediated suppression of MYCN protein.

UI MeSH Term Description Entries

Related Publications

Terutaka Tanimoto, and Hiroshi Tazawa, and Takeshi Ieda, and Hiroshi Nouso, and Morimichi Tani, and Takanori Oyama, and Yasuo Urata, and Shunsuke Kagawa, and Takuo Noda, and Toshiyoshi Fujiwara
Lysis of MYCN-amplified neuroblastoma cells by MYCN peptide-specific cytotoxic T lymphocytes.
April 2000, Cancer research,
Terutaka Tanimoto, and Hiroshi Tazawa, and Takeshi Ieda, and Hiroshi Nouso, and Morimichi Tani, and Takanori Oyama, and Yasuo Urata, and Shunsuke Kagawa, and Takuo Noda, and Toshiyoshi Fujiwara
Locoregional MYCN-amplified neuroblastoma.
October 2012, Pediatric blood & cancer,
Terutaka Tanimoto, and Hiroshi Tazawa, and Takeshi Ieda, and Hiroshi Nouso, and Morimichi Tani, and Takanori Oyama, and Yasuo Urata, and Shunsuke Kagawa, and Takuo Noda, and Toshiyoshi Fujiwara
MYCN mRNA degradation and cancer suppression by a selective small-molecule inhibitor in MYCN-amplified neuroblastoma.
January 2022, Frontiers in oncology,
Terutaka Tanimoto, and Hiroshi Tazawa, and Takeshi Ieda, and Hiroshi Nouso, and Morimichi Tani, and Takanori Oyama, and Yasuo Urata, and Shunsuke Kagawa, and Takuo Noda, and Toshiyoshi Fujiwara
Expulsion of amplified MYCN from neuroblastoma tumor cells.
January 2000, Cancer genetics and cytogenetics,
Terutaka Tanimoto, and Hiroshi Tazawa, and Takeshi Ieda, and Hiroshi Nouso, and Morimichi Tani, and Takanori Oyama, and Yasuo Urata, and Shunsuke Kagawa, and Takuo Noda, and Toshiyoshi Fujiwara
Epigenetic Dysregulation in MYCN-Amplified Neuroblastoma.
December 2023, International journal of molecular sciences,
Terutaka Tanimoto, and Hiroshi Tazawa, and Takeshi Ieda, and Hiroshi Nouso, and Morimichi Tani, and Takanori Oyama, and Yasuo Urata, and Shunsuke Kagawa, and Takuo Noda, and Toshiyoshi Fujiwara
4-Hydroxychalcone Induces Cell Death via Oxidative Stress in MYCN-Amplified Human Neuroblastoma Cells.
January 2019, Oxidative medicine and cellular longevity,
Terutaka Tanimoto, and Hiroshi Tazawa, and Takeshi Ieda, and Hiroshi Nouso, and Morimichi Tani, and Takanori Oyama, and Yasuo Urata, and Shunsuke Kagawa, and Takuo Noda, and Toshiyoshi Fujiwara
Aryl hydrocarbon receptor is a tumor promoter in MYCN-amplified neuroblastoma cells through suppression of differentiation.
November 2023, iScience,
Terutaka Tanimoto, and Hiroshi Tazawa, and Takeshi Ieda, and Hiroshi Nouso, and Morimichi Tani, and Takanori Oyama, and Yasuo Urata, and Shunsuke Kagawa, and Takuo Noda, and Toshiyoshi Fujiwara
MYCN‑amplified neuroblastoma cell‑derived exosomal miR‑17‑5p promotes proliferation and migration of non‑MYCN amplified cells.
April 2021, Molecular medicine reports,
Terutaka Tanimoto, and Hiroshi Tazawa, and Takeshi Ieda, and Hiroshi Nouso, and Morimichi Tani, and Takanori Oyama, and Yasuo Urata, and Shunsuke Kagawa, and Takuo Noda, and Toshiyoshi Fujiwara
Induction of MYCN-amplified neuroblastoma differentiation through NMYC suppression using PPAR-γ antagonist.
November 2023, Journal of clinical biochemistry and nutrition,
Terutaka Tanimoto, and Hiroshi Tazawa, and Takeshi Ieda, and Hiroshi Nouso, and Morimichi Tani, and Takanori Oyama, and Yasuo Urata, and Shunsuke Kagawa, and Takuo Noda, and Toshiyoshi Fujiwara
The MicroRNA Landscape of MYCN-Amplified Neuroblastoma.
January 2021, Frontiers in oncology,
Copied contents to your clipboard!